By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cancer diagnostics firm Dako said today it is collaborating with Genentech on the regulatory submission in the US of two Dako tests as companion diagnostics for Genentech's investigational drug candidate for breast cancer.

The companies will partner on submitting Dako's HercepTest and Her2 FISH pharmDx to the US Food and Drug Administration as companion diagnostics for Genentech's pertuzumab as a treatment for patients with advanced HER2-positive breast cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.